Accesswire · 30 Sept 2026positive
Ainos announced that it completed the required data delivery and technology transfer under its VELDONA license agreement, with the licensing partner confirming completion in writing on September 29. This fulfillment triggers a $600,000 initial license payment payable within 15 business days.
Why it matters — This milestone confirms progress under Ainos's VELDONA license agreement and activates a contractual payment to the company.
Accesswire · 29 Sept 2026positive
Ainos announced it has completed delivery of all 1,400 AI Nose systems to ASE Technology Holding under a $2.1 million, three-year agreement. Preparations are underway for a larger-scale second-phase deployment specified in an existing memorandum of understanding, building on the first-phase deployment experience, with the advanced packaging deployment marking progress for Ainos' Chemical Intelligence platform and its commercial advancement in advanced wafer fabrication.
Why it matters — This completed delivery represents a milestone in Ainos' commercial deployment of its AI Nose technology and sets the stage for a potentially larger second-phase deployment under an existing MOU.
Accesswire · 28 Sept 2026positive
Ainos detailed the financial and strategic benefits of its VELDONA License Agreement, including an initial $600,000 license fee and the partner assuming clinical and regulatory funding and execution. The company retains platform ownership and 25% of applicable net sublicensing revenue, with economic participation extending beyond the $10 million licensing framework.
Why it matters — AIMD watchers would care because the partner-funded development model reduces Ainos' capital and staffing requirements while creating revenue opportunities that extend beyond the initial license fee ahead of drug approval.
Accesswire · 24 Sept 2026positive
Ainos, Inc. announced it has signed a VELDONA License Agreement with BioPhoenix Co., Ltd., establishing a collaboration framework with a potential aggregate value of $10 million. BioPhoenix will fund and advance clinical and regulatory development for two initial indications, while Ainos retains core platform ownership, product supply opportunities, and participation in downstream commercial revenue.
Why it matters — AIMD watchers would care because the partner-funded VELDONA development agreement could expand Ainos' clinical pipeline and create additional revenue streams without diluting the company's core platform ownership.
Accesswire · 16 Sept 2026positive
Ainos highlighted a new research update from VASRO GmbH pointing to strengthening commercial momentum for its AI Nose platform, including the transition of its front-end semiconductor program from validation to initial commercial orders, an established $2.1 million back-end subscription program, and its proprietary real-world chemical dataset surpassing 1 billion records.
Why it matters — AIMD watchers would care because these milestones signal that Ainos' semiconductor-focused AI Nose platform is advancing beyond validation into commercial ordering and expanding its proprietary dataset, indicating growing commercial scale.
